In addition, the team found, TAVR’s two-year quality-adjusted life expectancy was 1.71 quality-adjusted life years—more than the 1.66 quality-adjusted life years for SAVR.
“Data from the PARTNER 3 trial show that for patients with severe aortic stenosis and low surgical risk, TAVR is cost-saving compared with SAVR at two-year follow-up and is projected to be highly cost effective over a lifetime horizon—as long as there are no major differences in late mortality between the two strategies,” David J. Cohen, MD, director of clinical and outcomes research for the Cardiovascular Research Foundation and director of academic affairs for St. Francis Hospital and Heart Center, said in a statement. “Given the importance of long-term outcomes in these projections, extended follow-up through at least 10 years will be critical to validate these findings.”
Edwards Lifesciences, the manufacturer behind the Sapien 3 valve, did fund this study. Also, Cohen reported a working relationship with Edwards Lifesciences, as well as other industry vendors.
More information on TCT 2021 is available here.
"low" - Google News
November 05, 2021 at 11:45PM
https://ift.tt/3katbQV
TAVR more cost-effective than surgery for low-risk patients, new 2-year study confirms - Cardiovascular Business
"low" - Google News
https://ift.tt/2z1WHDx
Bagikan Berita Ini
0 Response to "TAVR more cost-effective than surgery for low-risk patients, new 2-year study confirms - Cardiovascular Business"
Post a Comment